Immunogenicity and Safety of a Fully Liquid DTaP-IPV-Hep B-PRP-T Vaccine at 2-4-6 Months of Age in Peru

Claudio Lanata¹, Betzana Zambrano², Lucie Ecker¹, Isabel Amemiya¹, Ana Gil¹ and Eduardo Santos Lima³*

¹Instituto de Investigación Nutricional, Lima, Peru
²Sanofi Pasteur, Montevideo, Uruguay
³Clinical Development, Sanofi Pasteur, Lyon, France

Abstract

Objectives: To assess the immunogenicity and safety of a new candidate, fully liquid, hexavalent DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim™, an AcXim family vaccine) compared to a licensed hexavalent DTaP-IPV-Hep B/PRP-T vaccine (Infanrix hexa™) in Peru.

Methods: Infants born to HBsAg seronegative mothers and who had not received a hepatitis B vaccine prior to entry into the study were randomized to receive either Hexaxim™ (Group 1) or Infanrix hexa™ (Group 2) at 2, 4, and 6 months of age. Seroprotection (SP) rate for hepatitis B (anti-HBs antibody concentration ≥10 mIU/mL) was analysed for non-inferiority (Group 1 minus Group 2) 1 month post-primary series. Anti-diphtheria and anti-polysaccharide ribitol phosphate (PRP) antibody responses were analysed descriptively. Safety was analysed from parental reports.

Results: Seroprotection rate for anti-HBs antibody titers ≥10 mIU/mL was high in both groups (≥99.2%) and non-inferiority was demonstrated (lower bound of the 95% CI for the difference was -4.17, above the pre-defined delta [-10%]). Post-primary SP rates for anti-diphtheria (≥95.5% ≥0.01 IU/mL), anti-PRP (≥99.2% ≥0.15 µg/mL), and anti-HBs ≥100 mIU/mL (≥93.9%), were similar in each group. Both vaccines were well tolerated. The incidence of serious adverse events was low and similar in each group, and none was considered to be vaccine related.

Conclusions: In a 2, 4, 6 month schedule in Peruvian infants, the investigational DTaP-IPV-Hep B-PRP-T fully liquid vaccine provided high immunogenicity for HBs, diphtheria and PRP vaccine antigens that was comparable to the licensed hexavalent vaccine. Both vaccines had a similar safety profile.

Keywords: Vaccine; Hexavalent; Pediatric; Combination; Immunization

Introduction

The investigational hexavalent vaccine (Hexaxim™) is fully liquid and part of Sanofi Pasteur’s AcXim family, which includes the established tetra- and pentavalent vaccines Tetraxim®/Tetravac® and Pentaxim®/Pentavac®. It combines a new Hansenula polymorpha-derived and thimerosal-free hepatitis B (Hep B) antigen [1-3] with well-established diphtheria toxoid (D), tetanus toxoid (T), acellular (2-component [pertussis toxoid (PT) and filamentous hemagglutinin (FHA)] pertussis (aP), inactivated poliovirus (IPV), and Haemophilus influenzae type b polysaccharide conjugated to tetanus protein (PRP-T) antigens to produce a new hexavalent vaccine. The IPV and PRP-T antigens are WHO pre-qualified [4] as standalone vaccines (Imovax® Polio and ActHib®, respectively). The immunogenicity and safety of the new Hep B antigen have been described following both monovalent administration to adults and adolescents [5] as well as following administration of the new hexavalent vaccine in several pediatric clinical studies in a range of ethnic populations and administration schedules [6-8].

Accepted advantages of combination vaccines include a reduced number of injections coupled with increased compliance to increasingly challenging pediatric vaccination schedules, leading to improved disease control with associated reduced direct and indirect costs [9]. The routine use of combination vaccines has been crucial in reducing the incidence of childhood diseases [9]. However, regional disparities remain, such as the use of combination vaccines based on aP versus whole-cell pertussis (wP) vaccines or the inclusion or not of hepatitis B and/or IPV versus the use of a standalone hepatitis B vaccine and/or the oral poliovirus vaccine (OPV). The investigational vaccine, including aP and IPV valences, aims to provide protection against six diseases that are considered by WHO to be priorities and is presented in a ready-to-use, fully liquid formulation.

Being a fully liquid vaccine, Hexaxim minimizes human error associated with vaccine re-constitution, and helps to improve vaccination compliance. But more importantly, the introduction of a second hexavalent vaccine against D, T, P, IPV, hepatitis B, and Hib, will be vital in the event of global production and supply ruptures, which can arise intermittently even when established, well-monitored and controlled processes are in place. In such instances, the availability of a second hexavalent vaccine will mean that vaccination coverage rates could be more easily maintained globally, minimising potential outbreaks of these six pediatric infectious diseases.

This clinical study was performed to document immunogenicity and safety data in a Peruvian pediatric population following administration of the investigational hexavalent vaccine at 2, 4 and 6
months of age. As the Hep B antigen is the novel component of the investigational vaccine, the non-inferiority of Hep B seroprotection (SP) compared to a licensed vaccine comparator was the primary objective of this study, the immunogenicity of the other vaccine components having been demonstrated in previous studies with this [6-8] and other AcXim family vaccines that include some of the same antigens [10] - for the two-component aP antigen, a recently published review concluded high and similar immunogenicity irrespective of the study population and immunization schedule [11]. In our study, we also included the immunogenicity of the PRP antigen to compare the response following its administration as a valence of the fully liquid, investigational vaccine to its administration as a lyophilized constituent of the comparator vaccine. Finally, we describe the immunogenicity of the D antigen and include anti-D concentration data prior to the first dose (as well as after the final dose) to provide an indication of the level of passively transmitted maternal anti-D antibodies and their effect on the post-primary series response.

Materials and Methods

Study design and participants

This was a Phase III, observer-blind, randomized, controlled study performed in a single centre in Peru (ClinicalTrials.gov identifier: NCT00831753). Healthy 2-month-old infants who were born at full-term (≥37 weeks) and with birth weight ≥2.5 kg were included in the study, which took place between May 2008 and May 2009. Mothers were screened for hepatitis B surface antigen (HBsAg) in either the last 30 days of pregnancy (≥36 weeks of amenorrhoea) or in the first 30 days post-partum; only babies born to HBsAg-negative mothers were considered for inclusion in the study. In addition, no hepatitis B vaccine was to have been administered prior to entry into the study at 2 months of age.

Other criteria for exclusion were if the infant was febrile (temperature >38.0°C), had taken part in or was planning to take part in a clinical study in parallel, was immunodeficient, had received any blood-derived product since birth, or if any illness contraindicated vaccination had been administered in the 4 weeks prior to the first study vaccination, if any vaccination was planned during the study (other than the study vaccines, rotavirus and pneumococcal conjugate vaccines having been demonstrated in previous studies with this investigational vaccine to its administration as a lyophilized constituent of the comparator vaccine). Finally, we describe the immunogenicity of the D antigen and include anti-D concentration data prior to the first dose (as well as after the final dose) to provide an indication of the level of passively transmitted maternal anti-D antibodies and their effect on the post-primary series response.

Follow-up inclusion in the study, a randomization list created under the responsibility of Sanofi Pasteur’s statistics department was used to assign infants to receive either the investigational DTaP-IPV-Hep B-PRP-T vaccine (Group 1) or the licensed DTaP-IPV-Hep B/PRP-T comparator (Group 2).

The protocol and informed consent form and their amendments were approved by the independent ethics committees of the study centre (Instituto de Investigación Nutricional, Lima, Peru) and by the Peruvian Ministry of Health. The study was done in accordance with the recommendations of the Declaration of Helsinki (Edinburgh revision, October 2000) and International Conference on Harmonisation (ICH) Good Clinical Practice (GCP), and with applicable national and local requirements.

Vaccines and vaccine administration

The investigational DTaP-IPV-Hep B-PRP-T vaccine (batch number S4009F04) (Hexaxim®) was manufactured by Sanofi Pasteur and supplied in pre-filled 0.5 mL syringes that were shaken gently before injection. The needle size was 25G/16 mm. Each 0.5 mL dose was preservative-free and contained ≥20 IU diphtheria toxoid, ≥40 IU tetanus toxoid, 25 µg pertussis toxoid (PT), 25 µg filamentous hemagglutinin (FHA); 40, 8 and 32 D-antigen units of IPV type 1, 2 and 3, respectively, 12 µg of Hemophilus influenzae type b polysaccharide conjugated to tetanus toxoid, 10 µg HBsAg, and 0.6 mg aluminum hydroxide (total aluminum content of 0.6 mg per dose).

The control DTaP-IPV-Hep B//PRP-T vaccine (batch number A21CA310C) (Infanrix hexa®) was manufactured by GlaxoSmithKline Biologicals and supplied as two separate components (a DTaP-Hep B-IPV suspension in a pre-filled syringe and lyophilized PRP-T as a white pellet in a glass vial) that were reconstituted as a 0.5 mL dose immediately prior to injection. The needle size was 25G/25 mm. Each dose contained 2-phenoxethanol as preservative, ≥30 IU of diphtheria toxoid, 40 IU tetanus toxoid, 25 µg PT, 25 µg FHA, 8 µg pertactin, 40, 8 and 32 D-antigen units of IPV type 1, 2 and 3, respectively, 10 µg of Hemophilus influenzae type b polysaccharide conjugated to 20-40 µg tetanus toxoid, 10 µg HBsAg the PRP-T and HBsAg were adsorbed on 1.45 mg aluminum phosphate and the D, T; PT, FHA and pertactin were adsorbed on 0.95 mg hydrated aluminum oxide (total aluminum content of 0.8 mg per dose).

The investigational and control vaccines were administered intramuscularly into the anterolateral aspect of the—preferably right—thigh.

Serology

A 4 mL blood sample was taken at 2 months of age (i.e. prior to the first primary series vaccination) for determination of anti-D antibody concentration and a 5 mL sample was taken at 7 months of age (i.e. 1 month after the third vaccination) for assessment of antibodies to anti-D, anti-PRP and anti-Hep B. We focused on these three antigens for the reasons described in the Introduction, and elucidated in the Discussion.

Serological analyses were done at the Sanofi Pasteur Global Clinical Immunology Laboratory in the USA. Anti-Hep B antibody concentrations were measured using the commercially-available VITROS® anti-HBs assay (Ortho-Clinical Diagnostics, Inc.); anti-D antibody concentrations were measured by a toxoid neutralization test; and anti-PRP antibody concentrations were measured by a Farr-type radioimmunoassay (RIA).

Reactogenicity and safety

For routine evaluation of reactogenicity (pre-defined [solicited] adverse events) and safety, each participant was observed by the Investigator for 30 minutes after each vaccination to monitor for any immediate adverse events. In addition, for solicited injection site (pain, erythema, and swelling) and systemic (pyrexia, vomiting, crying, somnolence, anorexia, and irritability) reactions1, daily intensity/measurement was recorded by the parent(s)/legally responsible representative using diary cards for 7 days following each vaccination (and pertinent details if ongoing after that time). The parent(s)/legally responsible representative also recorded the start/stop date, intensity/measurement and other pertinent details of any non-solicited events to the next visit. All non-solicited injection site events were considered to be related to the vaccination and so were recorded as non-solicited injection site reactions; the relationship to the vaccination for non-
solicited systemic events was assessed by the Investigator. Each adverse event was categorized as Grade 1 (mild), Grade 2 (moderate) or Grade 3 (severe) by the investigators. While rectal temperature was measured at study visits by the Investigator, axillary rather than rectal temperature was measured by the parent(s)/legally responsible representative between visits for cultural and compliance reasons. No temperature conversion calculation was made for the route of measurement used.

Serious adverse events (SAEs) were collected throughout the study, until 6 months after the final primary series vaccination.

**Statistical analyses**

The primary objective of the study was to demonstrate non-inferiority for Hep B SP rate, based on a threshold of 10 mIU/mL at 1 month after the three-dose primary vaccination series, for the investigational DTaP-IPV-Hep B-PRP-T vaccine compared to the licensed DTaP-IPV-Hep B/PRP-T comparator. The non-inferiority comparison was based on the difference (Group 1 minus Group 2) in SP rate for anti-Hep B antibody concentrations ≥10 mIU/mL, with non-inferiority being concluded if the lower bound of the two-sided 95% confidence interval (CI) of the difference was above -10%. The 95% CI for the difference was calculated based on the Wilson score method without continuity correction as described by Newcombe [12].

Secondary objectives included further description of the immunogenicity of the Hep B antigen, as well as the D and PRP antigens for both the investigational and control vaccines. Geometric mean antibody concentrations were calculated with their normal approximation method, and the percentages of participants achieving pre-defined thresholds (Table 1) were calculated with their 95% CIs using the exact binomial distribution for percentages (Clopper-Pearson method, quoted by Newcombe [13]). Additionally, safety was analysed as a secondary objective in each group (% of participants with a particular event and associated 95% CI calculated using the exact binomial distribution for percentages) (Clopper-Pearson method, quoted by Newcombe [13]).

It was planned to include 266 participants (133 in each group); this sample size calculation was done using the Farrington and Manning formula [14] based on type I error of 2.5% (one-sided hypothesis) to provide an overall power of 90% for the primary objective, assuming a SP rate of 96% and an attrition rate of 15%.

The Intent to Treat (ITT) analysis set comprised all participants who received at least one dose of vaccine, analysed by randomisation group. The Per Protocol (PP) analysis set comprised ITT participants who received the three doses of primary series with no protocol deviations. The Safety Analysis Set comprised participants who received at least one dose of study vaccine, analysed by vaccine received. The primary hypothesis of non-inferiority for Group 1 minus Group 2 immunogenicity was tested on the PP analysis set and confirmed using the ITT analysis set. The Safety Analysis Set was used for the safety analysis.

All analyses were done using SAS software, Version 9.1 (SAS Institute, Cary, NC, USA).

### Table 1: Summary of seroprotection rates and geometric mean concentrations (per protocol analysis set).

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Timepoint</th>
<th>Endpoint</th>
<th>% of participants</th>
<th>GMC (IU/mL) or log_{10} (GMC) (95% CI or log_{10} (SD))</th>
<th>% of participants</th>
<th>GMC (IU/mL) or log_{10} (GMC) (95% CI or log_{10} (SD))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Hep B</td>
<td>Post-Dose 3</td>
<td>≥10 mIU/mL</td>
<td>99.2%</td>
<td>(95.9, 100.0)</td>
<td>100.0%</td>
<td>(97.2, 100.0)</td>
</tr>
<tr>
<td>Anti-Hep B</td>
<td>Post-Dose 3</td>
<td>≥100 mIU/mL</td>
<td>93.9%</td>
<td>(88.4, 97.3)</td>
<td>99.2%</td>
<td>(96.8, 100.0)</td>
</tr>
<tr>
<td>Anti-Hep B</td>
<td>Post-Dose 3</td>
<td>≥0.15 μg/mL</td>
<td>100.0%</td>
<td>(97.2, 100.0)</td>
<td>99.2%</td>
<td>(95.8, 100.0)</td>
</tr>
<tr>
<td>Anti-D</td>
<td>Pre-Dose 1</td>
<td>≥0.01 IU/mL</td>
<td>82.6%</td>
<td>(75.0, 88.6)</td>
<td>84.6%</td>
<td>(77.2, 90.3)</td>
</tr>
<tr>
<td>Anti-D</td>
<td>Pre-Dose 1</td>
<td>≥0.1 IU/mL</td>
<td>66.7%</td>
<td>(57.9, 74.6)</td>
<td>70.0%</td>
<td>(61.3, 77.7)</td>
</tr>
<tr>
<td>Anti-D</td>
<td>Pre-Dose 1</td>
<td>≥0.01 IU/mL</td>
<td>95.5%</td>
<td>(90.4, 98.3)</td>
<td>100.0%</td>
<td>(97.2, 100.0)</td>
</tr>
<tr>
<td>Anti-D</td>
<td>Pre-Dose 1</td>
<td>≥0.1 IU/mL</td>
<td>58.3%</td>
<td>(49.4, 66.8)</td>
<td>65.4%</td>
<td>(56.5, 73.5)</td>
</tr>
<tr>
<td>Anti-D</td>
<td>Post-Dose 3</td>
<td>≥0.01 IU/mL</td>
<td>100.0%</td>
<td>(97.2, 100.0)</td>
<td>99.2%</td>
<td>(95.8, 100.0)</td>
</tr>
<tr>
<td>Anti-D</td>
<td>Post-Dose 3</td>
<td>≥0.01 IU/mL</td>
<td>58.3%</td>
<td>(49.4, 66.8)</td>
<td>65.4%</td>
<td>(56.5, 73.5)</td>
</tr>
</tbody>
</table>

Group 1=DTaP-IPV-Hep B-PRP-T at 2, 4, 6 months
Group 2=DTaP-IPV-Hep B/PRP-T at 2, 4, 6 months

Data are % of participants (95% CI) or geometric mean concentration (GMC) (calculated according to the number of participants available for the endpoint); N=number of participants in the per protocol analysis set; NC=not calculated (as not primary objective)

---

2Grade 1, 2, and 3 pains were defined as ‘minor reaction when injection site is touched,’ ‘cries and protests when injection site is touched,’ and ‘cries when injected limb is moved or the movement of the injected limb is reduced.’ For erythema and swelling, a diameter of <2.5 cm was assessed as Grade 1, from 2.5 to <5 cm as Grade 2 and ≥5 cm as Grade 3. Grade 1, 2, and 3 fever were defined as temperature ≥38.0°C–<38.5°C, ≥38.5°C–<39.0°C, and ≥39.5°C, respectively. Other systemic symptoms were defined as: vomiting (Grade 1=Grade 2, 1 to 5 episodes/day; Grade 3, ≥6 episodes/day) (day) abnormal crying (Grade 1–Grade 2, 53 hours; Grade 3, ≥3 hours), drowsiness, (Grade 1=Grade 2, unusually sleepy; Grade 3, sleepy most of the time) loss of appetite (Grade 1=Grade 2, missed 1 to 2 meals; Grade 3, missed ≥3 meals) and irritability (Grade 1=Grade 2, easily consolable or needs increased attention; Grade 3, inconsolable).
Results

Participants studied

A total of 266 participants were included in the study as planned, although three participants failed to provide a baseline blood sample and so were withdrawn from the study before receiving the first vaccination. A total of 263 participants received three primary series vaccinations (132 in Group 1 and 131 in Group 2) and were included in the ITT and Safety Analysis Sets. One participant in Group 2 was excluded from the PP analysis set as no post-vaccination blood sample was available, leaving 132 (Group 1) and 130 (Group 2) participants in the PP analysis set and satisfying the sample size power calculation for the primary objective. The participant disposition is summarized in Figure 1.

There were no clinically important differences in demographic characteristics between the two groups.

Immunogenicity

The observed SP rates 1 month after the third dose were high anti-Hep B, anti-PRP and anti-D in both groups (Table 1). For anti-Hep B, non-inferiority for SP (concentration ≥10 mIU/mL) was demonstrated for Group 1 compared to Group 2 (99.2% in Group 1 and 100.0% in Group 2) as the lower bound of the 95% CI for the difference was -4.17 (above the pre-defined lower limit of -10) (Table 1).

After the third dose, at least 99.2% and 83.8% of participants had anti-PRP ≥0.15 and 1.0 µg/mL in each group. The SP rate was at least 95.5% for anti-D ≥ 0.01 IU/mL, and at least 93.9% for anti-Hep B ≥100 mIU/mL in each group.

As for SP rates, anti-Hep B, anti-PRP and anti-D GMCs 1 month after the third primary series vaccination were descriptively similar for each group (Table 1). In addition, anti-D SP rates and GMC were high prior to the first vaccination, and the anti-D antibody GMC decreased from pre-first dose to post-third dose.

The results for the ITT analysis set (not presented) supported those for the PP analysis set.

Safety and tolerability

No immediate adverse events (i.e. those occurring in the 30 minutes after vaccination) were reported in either group. Solicited injection site and systemic reactions (all grades and Grade 3) are summarized in Table 2. Overall the frequency of each solicited reaction was similar between groups and there was no difference between groups in the frequency of Grade 3 reactions for any solicited injection site or solicited systemic reaction.

The frequency of unsolicited events (systemic and injection site combined) within 7 days after any vaccination was similar in each group (56.1% of participants experiencing at least one unsolicited adverse event in Group 1 and 61.8% in Group 2) and to Day 30 (81.8% of participants in Group 1 and 87.8% in Group 2). The most common unsolicited events were nasopharyngitis and abdominal pain, and most were Grade 1 or 2 in intensity, occurred in the 7 days after vaccination, resolved spontaneously, and were not considered to be related to the vaccination.

In Groups 1 and 2 respectively, 3 (2.3%) and 2 (1.5%) participants experienced an SAE in the period up to 30 days after the third vaccination. These were a hepatic cyst (Group 2), cellulitis (Group 1), viral pneumonia (Group 1), and bronchial obstruction (Group 1 and Group 2), and in all cases the participant recovered without sequelae. None of these SAEs was considered by the Investigators to be related to the vaccination.

No participant died during the study and none was withdrawn due to an adverse event.

Discussion

The primary objective of the study was met, namely to demonstrate non-inferiority in terms of SP rate (≥10 mIU/mL) for the new Hep B component of the investigational DTaP-IPV-Hep B-PRP-T fully liquid vaccine compared to the licensed DTaP-IPV-Hep B/PRP-T comparator. Furthermore, the post primary series GMCs and the percentage of participants with a concentration ≥100 mIU/mL,
**Table 2:** Summary of solicited injection site and systemic adverse reactions occurring within 7 days after any dose of vaccine (safety analysis set).

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Severity</th>
<th>Group 1 (N=132)</th>
<th>Group 2 (N=131)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>Any</td>
<td>77.3 (69.2-84.1)</td>
<td>77.1 (68.9-84.0)</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>7.6 (3.7-13.5)</td>
<td>4.6 (1.7-9.7)</td>
</tr>
<tr>
<td>Erythema</td>
<td>Any</td>
<td>59.1 (50.2-67.6)</td>
<td>50.4 (41.5-59.2)</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>2.3 (0.5-6.5)</td>
<td>3.8 (1.3-8.3)</td>
</tr>
<tr>
<td>Swelling</td>
<td>Any</td>
<td>40.9 (32.4-49.8)</td>
<td>39.7 (31.3-48.8)</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>2.3 (0.5-6.5)</td>
<td>1.5 (0.2-2.5)</td>
</tr>
</tbody>
</table>

**Systemic Reactions:**

<table>
<thead>
<tr>
<th>Reaction</th>
<th>Severity</th>
<th>Group 1 (N=132)</th>
<th>Group 2 (N=131)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyrexia</td>
<td>Any</td>
<td>28.0 (20.0-36.3)</td>
<td>27.5 (20.0-36.0)</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>0.0 (0.0-2.8)</td>
<td>0.0 (0.0-2.8)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>Any</td>
<td>22.0 (15.2-30.0)</td>
<td>24.4 (17.3-32.7)</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>0.0 (0.0-2.8)</td>
<td>0.0 (0.0-2.8)</td>
</tr>
<tr>
<td>Crying</td>
<td>Any</td>
<td>75.8 (67.5-82.8)</td>
<td>71.0 (62.4-78.6)</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>0.8 (0.0-4.1)</td>
<td>0.8 (0.0-4.2)</td>
</tr>
<tr>
<td>Somnolence</td>
<td>Any</td>
<td>55.3 (46.4-64.0)</td>
<td>62.6 (53.7-70.9)</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>1.5 (0.2-2.5)</td>
<td>1.5 (0.2-2.5)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>Any</td>
<td>40.9 (32.4-49.8)</td>
<td>44.3 (35.6-53.2)</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>0.0 (0.0-2.8)</td>
<td>0.8 (0.0-4.2)</td>
</tr>
<tr>
<td>Irritability</td>
<td>Any</td>
<td>75.8 (67.5-82.8)</td>
<td>74.8 (66.5-82.0)</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>1.5 (0.2-2.5)</td>
<td>0.6 (0.0-4.2)</td>
</tr>
</tbody>
</table>

Group 1=DTaP-IPV-Hep B-PRP-T at 2, 4, 6 months
Group 2=DTaP-IPV-Hep B at 2, 4, 6 months

The measurement of anti-D antibodies before and after the primary series was to document the putative presence of residual maternal antibodies post-natally and their effect on the post-natal response to vaccination. Our data show high SP rates against diphtheria prior to the first vaccination, resulting from the passive, maternally-acquired immunity. Although the percentage of participants with anti-diphtheria antibodies ≥0.01 IU/mL was higher after the primary series than before the first vaccination, our data show slightly reduced GMCs in both groups and a slightly reduced percentage of participants with a concentration ≥0.1 IU/mL after the primary series. This is a well documented phenomenon, having previously been described for the investigational vaccine [8] as well as for other pediatric diphtheria-containing vaccines [28-30].

The safety of the investigational vaccine was similar to that of the comparator vaccine, and confirmed its good safety profile documented in previous clinical studies [6-8].

**Conclusions**

The investigational DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim™) demonstrated high immunogenicity for the new Hep B antigen and for the PRP antigen (as part of a fully liquid, hexavalent presentation) that was similar to a licensed hexavalent comparator vaccine (with a lyophilized PRP antigen). Additionally, the assessment of anti-D antibodies confirmed the presence of maternal antibodies prior to the first dose and their inhibitory influence on the response to the primary vaccination series in terms of GMC (although in terms of the percentage of participants with a titer ≥0.01 mIU/mL, the post-vaccination SP rate was higher than pre-vaccination). The investigational vaccine demonstrated a good safety profile, consistent with that demonstrated in previous clinical studies with the same vaccine. The expanded use of such an aP-IPV-containing hexavalent vaccine could contribute to further improvement in vaccine coverage and an associated reduction in the burden of these six childhood diseases.

**Source of Financial Support**

This study was done with the financial support of Sanofi Pasteur, Lyon, France.

The results of this study were presented at the Sociedad Latinoamericana de Infectología Pediátrica (SLIPE), Dominican Republic, 25-28 May 2011.

**Acknowledgements**

We would like to acknowledge all the study staff who contributed to the study conduct and to all study participants and their parents/legal guardians.

In addition, we would like to thank the members of an independent data...
monitoring committee (IDMC) for periodic review of safety data during this study: Dr Edwin Asturias (Chairman and voting member), Prof Fred Zepp (voting member), Dr Alain Leizorovicz (voting member), Dr Rosanna Lagos (voting member), and Dr Nadine Bossard (non-voting member).

We would also like to thank Hector Verástegui of the Instituto de Investigación Nutricional for data management support and data checking, Dr Sandrine Lentsch-Graf (Hexamix™ Project Leader) for her valuable input, Mrs Siharm B’Chir for the statistical analyses, and Dr Andrew Lane for assistance in the preparation and development of the manuscript in accordance with the European Medical Writers Association guidelines and Good Publication Practice. SL-G, SB and AL are employees of Sanofi Pasteur.

Conflicts of Interest

This study was sponsored by Sanofi Pasteur who provided funding to the Instituto de Investigación Nutricional for this purpose. CL, LE, IA, and AG are employees of the Instituto de Investigación Nutricional but received no direct payment from Sanofi Pasteur. ESL and BZ are employees of Sanofi Pasteur. None of the IDMC members was employed by, or received payment from, Sanofi Pasteur (other than expenses).

References


